@article{455250e7ade343d7aa69855259724090,
title = "Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials",
author = "Crombag, \{Marie Rose B.S.\} and Haanen, \{John B.A.G.\} and Paul Baas and Beijnen, \{Jos H.\} and Huitema, \{Alwin D.R.\}",
note = "Funding Information: Through John B.A.G. Haanen, NKI has received compensation for advisory roles from Amgen, AZ, Bayer, BMS, Celsius Therapeutics, Gadeta, GSK, Immunocore, Ipsen, MSD, Merck Serono, Neon Therapeutics, Novartis, Pfizer, Roche/Genentech, Seattle Genetics; and NKI has received grants from MSD, BMS, Novartis, and Neon Therapeutics. The other authors declare no conflict of interest in connection with this paper. ",
year = "2020",
month = apr,
doi = "10.1016/j.jgo.2019.06.001",
language = "English",
volume = "11",
pages = "529--532",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Ltd.",
number = "3",
}